DO

Dr Martens PLCLSE Dr Martens Stock Report

Last reporting period 31 Mar, 2024

Updated 07 Nov, 2024

Last price

Market cap $B

0.689

Micro

Exchange

XLON - London Stock Exchange

DOCS.L Stock Analysis

DO

Avoid

Based on Eyestock quantitative analysis, DOCS.L`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

32/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

66.4 %

Greatly undervalued

Market cap $B

0.689

Dividend yield

3.48 %

Shares outstanding

1 000.77 B

Dr. Martens Plc engages in the manufacture and sale of footwear products. The firm operates through three reporting segments: Europe, the Middle East and Africa (EMEA); Americas; and Americas and Asia-Pacific (APAC). Its product categories include Originals, Fusion, Kids, Casual and Accessories. The Originals category comprises boots, shoes and loafers and also included within the Originals category is the Made in England range. The Fusion category comprises platform boots and shoes, sandals, heels, and refined take downs of the Originals. Within the Kids category is the mini-me range, which includes Originals, Fusion, and Casual collections. The company offers various accessories, such as shoe care, laces and socks, leather bags and small leather items. The firm operates in over 60 countries globally, through a range of modes: directly operated stores and ecommerce sites, wholesale partners and distributors.

View Section: Eyestock Rating